Wilke Anne C, Gökbuget Nicola
Department of Medicine II, Department for Hematology/Oncology, Goethe University, Frankfurt am Main, Germany.
Br J Haematol. 2025 Jul;207(1):27-42. doi: 10.1111/bjh.20134. Epub 2025 May 14.
Blinatumomab is a CD19 × CD3-directed bispecific T-cell engager that has become an essential backbone of acute B lymphoblastic leukaemia (BCP-ALL) treatment. It is used in relapsed/refractory disease, minimal residual disease (MRD), as well as in first-line treatment. Blinatumomab is particularly effective in MRD-positive BCP-ALL, inducing a high rate of deep molecular response, with very good overall tolerability. Very promising data are reported for the addition of blinatumomab to first-line therapy. This review focusses on new aspects of blinatumomab treatment in Philadelphia-negative BCP-ALL treatment in adult patients, including MRD-positive and relapsed/refractory disease, as well as reviewing recent clinical trials implementing blinatumomab into first-line therapy of BCP-ALL treatment.
博纳吐单抗是一种CD19×CD3导向的双特异性T细胞衔接器，已成为急性B淋巴细胞白血病（BCP-ALL）治疗的重要支柱。它用于复发/难治性疾病、微小残留病（MRD）以及一线治疗。博纳吐单抗在MRD阳性的BCP-ALL中特别有效，可诱导高比例的深度分子反应，总体耐受性良好。关于在一线治疗中添加博纳吐单抗的报道数据非常有前景。本综述重点关注博纳吐单抗在成人费城阴性BCP-ALL治疗中的新方面，包括MRD阳性和复发/难治性疾病，同时回顾了最近将博纳吐单抗应用于BCP-ALL一线治疗的临床试验。
